FDA
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
-
-
-
-
-
-
-
Summit Therapeutics launches phase III colorectal cancer trial
-
-
-
-
-
-
-
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

